Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Drug repurposing of propranolol

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.16
Views: 2139

Dr Pan Pantziarka - Anticancer Fund, UK

Dr Pantziarka speaks with ecancertv at ESMO 2016 about current efforts, and regulatory hurdles, towards the repurposing of medicines that are approved to treat other diseases, but have the potential to improve cancer patient outcomes.

He discusses how propranolol, a beta-blocker commonly prescribed to treat hypertension, might be a cheap and effective adjuvant in cancer therapy.

Dr Pantziarka is also joined by Dr Lydie Meheus of The Anticancer Fund, Belgium.

Read Dr Pantziarka and Dr Meheus’ article Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent here.

Drug repurposing was discussed further at a joint meeting of the BACR and ECMC, reported by ecancer here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation